Four monoclonal antibodies targeting CGRP — a peptide involved in migraine — show strong evidence for reducing migraine frequency with fewer side effects than older treatments.
2nd leading cause of disabilityMigraine affects millions globally, making effective prevention a major public health priority
What the researchers found
All four anti-CGRP monoclonal antibodies demonstrated significant reductions in monthly migraine days across multiple Phase 2-3 clinical trials, with favorable safety profiles compared to existing preventive treatments.
Why it matters
Migraine is the second leading cause of disability worldwide, and many patients fail existing preventive treatments or stop taking them due to side effects. CGRP-targeting antibodies represent the first migraine-specific preventive therapy class.
The numbers in context
4 monoclonal antibodies; migraine is 2nd leading cause of disability; monthly or quarterly dosing
How the study worked
Narrative review of published clinical trial data, ongoing trials, and pharmacological evidence for CGRP-targeting monoclonal antibodies in episodic and chronic migraine prevention.
Who was studied
Adults with episodic migraine, chronic migraine, or medication overuse headache
What this study cannot tell us
Review format — no new trial data. Long-term safety data beyond trial periods still accumulating. Cost and accessibility remain barriers for many patients. Does not address non-responders to anti-CGRP therapy.
How to read the evidence
Strong — reviews multiple Phase 2 and 3 randomized controlled trials with consistent positive results across all four antibodies.
When this study was published
Published in 2020; all four antibodies have since received FDA approval and real-world data continues to accumulate.
The bigger picture
These CGRP-targeting therapies represent a shift from repurposed drugs (beta-blockers, antidepressants, anticonvulsants) to mechanism-based migraine treatments, reflecting advances in understanding neuropeptide signaling in headache disorders.
Questions still open
- What percentage of migraine patients do not respond to anti-CGRP antibodies, and why?
- Are there long-term safety concerns with sustained CGRP blockade?
- How do these antibodies compare head-to-head in effectiveness and tolerability?
Common questions
What is CGRP and why does it matter for migraines?
How are these antibodies different from regular migraine medications?
Read the original research
Calcitonin Gene-Related Peptide Antagonists as a Savior in Episodic and Chronic Migraine: A Review.
Cureus, 12(6), e8711
Citation
Pervez, Hira; Khemani, Lavina; Khan, Mahrukh A; Seedat, Ahmed M; Roshan, Fnu. (2020). Calcitonin Gene-Related Peptide Antagonists as a Savior in Episodic and Chronic Migraine: A Review.. Cureus, 12(6), e8711. https://doi.org/10.7759/cureus.8711